the subsidiary in Argentina for EUR 2.0 
million. Partially compensated by interest revenues 
on bank accounts and investment bonds in 
relation to proton therapy projects for EUR 
1.7 million for the Proton Therapy and Other 
Accelerators segment; As at December 31, 2023, the group has 
recorded its share (50%) in the loss of PanTera 
SA/NV) for EUR 0.2 million. IBA does not 
account for its share of the loss in Cyclhad SAS 
and Normandy Hadrontherapy SAS above the 
value of its investment as the Group has no 
commitment to participate in any potential future 
capital increase.